A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
Article in Movement Disorders (June 2020)
The most recent citing publication is shown below. View this citation on Dimensions.
The Adenosinergic System
Overview of attention for book
Table of Contents
-
Altmetric BadgeBook Overview
-
Altmetric BadgeChapter 1 Adenosine A 2A Receptors: Localization and Function
-
Altmetric BadgeChapter 2 Allosteric Mechanisms in the Adenosine A 2A -Dopamine D 2 Receptor Heteromer
-
Altmetric BadgeChapter 3 Adenosine A 2A Receptor Antagonists in Drug Development
-
Altmetric BadgeChapter 4 Adenosine A 2A Receptors and Neurotrophic Factors: Relevance for Parkinson’s Disease
-
Altmetric BadgeChapter 5 Role of Adenosine A 2A Receptors in the Control of Neuroinflammation—Relevance for Parkinson’s Disease
-
Altmetric BadgeChapter 6 Purines in Parkinson’s: Adenosine A 2A Receptors and Urate as Targets for Neuroprotection
-
Altmetric BadgeChapter 7 Adenosine A 2A Receptor Antagonists as Drugs for Symptomatic Control of Parkinson’s Disease in Preclinical Studies
-
Altmetric BadgeChapter 8 Dopamine/Adenosine Interactions Related to Tremor in Animal Models of Parkinsonism
-
Altmetric BadgeChapter 9 Adenosine A 2A Receptor Antagonists in L-DOPA-Induced Motor Fluctuations
-
Altmetric BadgeChapter 10 Adenosine A 2A Receptor-Mediated Control of Non-Motor Functions in Parkinson’s Disease
-
Altmetric BadgeChapter 11 Imaging Studies with A 2A Receptor Antagonists
-
Altmetric BadgeChapter 12 Caffeine and Neuroprotection in Parkinson’s Disease
-
Altmetric BadgeChapter 13 The Story of Istradefylline—The First Approved A 2A Antagonist for the Treatment of Parkinson’s Disease
-
Altmetric BadgeChapter 14 Adenosinergic Receptor Antagonists: Clinical Experience in Parkinson’s Disease
-
Altmetric BadgeChapter 15 Adenosinergic Regulation of Sleep–Wake Behavior in the Basal Ganglia